Clinical evidence supports the feasibility of c-MET-targeted molecular imaging but remains limited by methodological heterogeneity, small sample sizes, limited biological validation, and variable diagnostic performance; larger, standardised studies are needed to establish the added clinical value and broader applicabil...
R. Verdijk, Stevie M. van der Mierde, Nataliia Berehova et al.· European Journal of Nuclear...· 0 citations
Mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis are reported and highlighted CD8+PD1+ T-cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.
Tynisha S. Rafael, Alberto Gil-Jimenez, L. Elst et al.· Cancer immunology research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.